|
|
||||||||
Clinical Chemistry, Vol 27, 1417-1420, Copyright © 1981 by American Association for Clinical Chemistry
DS McCann, J Tokarsky and RP Sorkin
Platelet activity may play a major role in the acute phase of atherosclerotic cardiovascular disease. To assess such activity, an assay for plasma thromboxane B2, a prostaglandin metabolite unique to platelets, is needed. The radioimmunoassay described here is based on a nonequilibrium incubation followed by a solid-phase second-antibody separation of bound from free thromboxane B2. No prior purification is required. Values for 22 normal subjects averaged 39.0 (SD 24.6) ng/L. The thromboxane B2 concentration of a plasma sample was 20.3 ng/L as compared with 37 micrograms/L in the corresponding serum. Plasma thromboxane B2 concentrations before and after ingestion of aspirin differed significantly (p less than 0.025). The biological half-life of intravenously injected [3H]thromboxane B2 in rabbits was 20 min. At the end of 2 h, 85% of the label was accounted for in urine, 7% in liver, and 5% in lung. Our assay is simple, reproducible, sensitive, and specific. It can be used to reflect acute events involving platelet aggregation.
The following articles in journals at HighWire Press have cited this article:
![]() |
K. Morioka, R. Muraoka, Y. Chiba, A. Ihaya, T. Kimura, H. Noguti, and T. Uesaka LEUKOCYTE AND PLATELET DEPLETION WITH A BLOOD CELL SEPARATOR: EFFECTS ON LUNG INJURY AFTER CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 45 - 54. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |